Comparing my PR draft to the actual PR. I think I did a good job. :)
Theirs:
- Primary endpoints of safety and tolerability met.
- Secondary endpoint: Statistically significant improvement in a measure of executive function (cognition) in research participants administered 250mg PBT2 daily (p=0.042).
- PBT2 250mg was also associated with a favourable signal in functional capacity.
- Preliminary evidence suggests PBT2 250mg reduced atrophy of brain tissue in areas affected in Huntington disease, seen in a pilot imaging sub-study.
- Company plans to advance PBT2 to a confirmatory Phase 3 clinical trial.
Mine was (after filling the endpoints and p values):
- The primary outcome (safety and tolerability) met. [Near word by word match].
- Also, even though the trial was not powered to show efficacy, <executive function (cognition)> reached statistical significance (<p=0.042>) for <250mg arm>. [Near perfect match again].
- Furthermore, <functional capacity, reduced atrophy of brain tissue> were close to reaching statistical significance for <250mg> <insert the p values less than 0.2>. [I thought there would be 3 or 4 such endpoints. They PR'ed only 2 endpoints]
- We are very excited. These results show that Pbt2 is an amazing drug. [I seriously thought they'll say that they are taking PBT2 to phase 3, but I just laughed at the thought. So not a complete match but close.]
